- Record: found
- Abstract: found
- Article: not found
Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
Shambhu Aryal
1 ,
Shalika B Katugaha
1
,
2 ,
Adam Cochrane
1
,
3 ,
Anne Whitney Brown
1 ,
Steven D Nathan
1 ,
Oksana A Shlobin
1 ,
Kareem Ahmad
1 ,
Lauren Marinak
1 ,
Jessica Chun
1 ,
Margaret Fregoso
1 ,
Shashank Desai
3 ,
Christopher King
1
Dec 2019
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Cytomegalovirus (CMV) infection is common in thoracic organ transplant recipients. Valganciclovir and ganciclovir are used for both prophylaxis and treatment of this infection, but intolerance and treatment failure are common. Letermovir has been demonstrated to reduce the risk of CMV infection when used for prophylaxis in allogeneic hematopoietic cell transplantation. However, there are no data on its efficacy in thoracic organ transplantation.